Nerissa Kreher Biography and Net Worth

Director of Rezolute

Dr. Kreher is a pediatric endocrinologist with more than 15 years of biotech industry experience in both Clinical Development and Medical Affairs. She has spent her career focused on drug development for patients with rare diseases in multiple therapeutic areas. Dr. Kreher currently serves as Chief Medical Officer of Alltrna. She was formerly the Chief Medical Officer of Entrada Therapeutics where she was responsible for Clinical Development, Medical Affairs, Regulatory, and Patient Advocacy. Her prior roles include Chief Medical Officer at Tiburio Therapeutics and Avrobio. Earlier in her career, she held roles of increasing responsibility at companies including Zafgen, Enobia (acquired by Alexion) and Genzyme. Dr. Kreher completed her pediatric endocrinology fellowship and pediatric residency at Riley Hospital for Children in Indianapolis. She received her M.D. from East Carolina University School of Medicine and her B.S. in Biology from The University of North Carolina at Chapel Hill.

What is Nerissa Kreher's net worth?: The estimated net worth of Nerissa Kreher is at least $364.49 thousand as of June 13th, 2025. Dr. Kreher owns 37,576 shares of Rezolute stock worth more than $364,487 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Kreher may own. Learn More about Nerissa Kreher's net worth.
How do I contact Nerissa Kreher?: The corporate mailing address for Dr. Kreher and other Rezolute executives is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. Rezolute can also be reached via phone at (650) 206-4507 and via email at [email protected]. Learn More on Nerissa Kreher's contact information.
Has Nerissa Kreher been buying or selling shares of Rezolute?: Nerissa Kreher has not been actively trading shares of Rezolute during the last ninety days. Most recently, on Friday, June 13th, Nerissa Kreher bought 3,076 shares of Rezolute stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $9,997.00. Following the completion of the transaction, the director now directly owns 37,576 shares of the company's stock, valued at $122,122. Learn More on Nerissa Kreher's trading history.
Who are Rezolute's active insiders?: Rezolute's insider roster includes Nevan Elam (CEO), Nevan Elam (Chief Executive Officer & Founder), Daron Evans (CFO), Wladimir Hogenhuis (Director), Wladimir Hogenhuis (Director), Young-Jin Kim (Director), Nerissa Kreher (Director), and Brian Roberts (Insider). Learn More on Rezolute's active insiders.
Are insiders buying or selling shares of Rezolute?: During the last twelve months, Rezolute insiders bought shares 10 times. They purchased a total of 1,299,405 shares worth more than $4,256,190.31. The most recent insider tranaction occured on June, 25th when insider Brian Kenneth Roberts bought 2,500 shares worth more than $10,950.00. Insiders at Rezolute own 14.8% of the company. Learn More about insider trades at Rezolute.
Information on this page was last updated on 6/25/2025.

Nerissa Kreher Insider Trading History at Rezolute

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/13/2025	Buy	3,076	$3.25	$9,997.00	37,576

Nerissa Kreher Buying and Selling Activity at Rezolute

Rezolute Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Today's Range

Now: $9.70

$9.28

$9.85

50 Day Range

MA: $9.37

$8.07

$10.76

2 Week Range

Now: $9.70

$2.21

$11.46

Volume

2,362,645 shs

Average Volume

1,471,023 shs

Market Capitalization

$899.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21